51
|
Cortés J, Cobo M, González CM, Gómez CD, Abalos M, Aristizábal BH. Environmental variation of PCDD/Fs and dl-PCBs in two tropical Andean Colombian cities using passive samplers. THE SCIENCE OF THE TOTAL ENVIRONMENT 2016; 568:614-623. [PMID: 26953138 DOI: 10.1016/j.scitotenv.2016.02.094] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/01/2015] [Revised: 02/13/2016] [Accepted: 02/13/2016] [Indexed: 06/05/2023]
Abstract
Passive air-sampling data of polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and dioxin-like polychlorinated biphenyls (dl-PCBs) taken in Manizales (a medium-sized city) and Bogotá (a megacity), Colombia, were analyzed in order to identify potential sources of pollution and the possible influence of meteorological variables like temperature and precipitation. The results indicate important differences in levels of PCDD/Fs and dl-PCBs between Bogotá and Manizales, attributed to differences in site characteristics and potential local/regional sources. Higher PCDD/Fs concentrations were observed in Bogotá (373fg/m(3)) compared to those observed in Manizales, with mean levels ranging from 64fg/m(3) in a residential zone to 151fg/m(3) around a vehicular-influenced area. Higher dl-PCBs concentrations were observed in the industrial area of Manizales compared to those observed in Bogotá, with mean levels of 6668fg/m(3) and 4388fg/m(3) respectively. In terms of PCDD/Fs congener distribution, there was a predominance of octachlorodibenzodioxin (OCDD) followed by 1,2,3,4,6,7.8-heptachlorodibenzofuran (HpCDF) congeners, with both cities showing higher levels in zones of high vehicular activity. Industrial influence was most evident in dl-PCB levels. In comparison to the mean levels of dl-PCB congeners obtained in the vehicular zones of Bogotá and Manizales, the industrially influenced sampling stations showed higher concentrations of dl-PCB congeners. Passive sampling results suggested that congener concentration profiles are characteristic of their different emission sources, and can be used to distinguish between their industrial or vehicular origins.
Collapse
|
52
|
Goss G, Lee K, Felip E, Cobo M, Syrigos K, Goker E, Georgioulias V, Guclu S, Isla D, Min Y, Morabito A, Dupuis N, Chand V, Solca F, Krämer N, Gibson N, Ehrnrooth E, Soria J. Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.38] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
53
|
Jänne P, van den Heuvel M, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile D, Lawrence D, Bowen K, Vansteenkiste J. Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.46] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
54
|
De Dios J, Martínez CL, Tato M, Morosini M, Cobo M, del Campo R, Cantón R. 92 Prevalence, colonization patterns and antibiotic susceptibility of Burkholderia cepacia complex isolates from a Spanish cystic fibrosis unit. J Cyst Fibros 2016. [DOI: 10.1016/s1569-1993(16)30331-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
55
|
Park K, Li W, Zhou C, Felip E, Cobo M, Goss G, Soria JC, Syrigos K, Krämer N, Chand V, Solca F, Lu S. 443P Phase III trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv532.27] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
56
|
Goss G, Felip E, Cobo M, Lu S, Syrigos K, Li K, Zhou C, Park K, Solca F, Krämer N, Chand V, Soria J. 3084 Phase III trial of afatinib vs erlotinib in patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31725-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
57
|
Popat S, Felip E, Cobo M, Fulop A, Dayen C, Trigo J, Gregg R, Waller C, Gordon J, Lorence R, Wang B, Chand V, Hirsh V. 3085 Second-line afatinib vs erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung: patient-reported outcome (PRO) data from the global LUX-Lung 8 (LL8) Phase III trial. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31726-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
58
|
Caballero J, Vindel A, Tato M, Cobo M, Cantón R, Del Campo R. WS19.2 Staphylococcus aureus population from cystic fibrosis patients in Spain: Results from a point-prevalence multicentre study. J Cyst Fibros 2015. [DOI: 10.1016/s1569-1993(15)30109-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
59
|
Quoix E, Nemunaitis J, Papai Z, Lena H, Genet D, Louis C, Cobo M, Al Farhat Y, Marie-Bastien B, Limacher J. TG4010 Immunotherapy Combined with First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC). Phase 2B Results of the Time Study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv050.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
60
|
de Castro J, Cobo M, Isla D, Puente J, Reguart N, Cabeza B, Gayete A, Sánchez M, Torres MI, Ferreirós J. Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2014; 17:11-23. [PMID: 25373531 DOI: 10.1007/s12094-014-1231-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Accepted: 09/18/2014] [Indexed: 12/25/2022]
Abstract
The last decade has seen substantial progress in the diagnostic and therapeutic approach to lung cancer, thus meaning that its prognosis has improved. The Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology have therefore produced a national consensus statement to make recommendations for radiological diagnosis and assessment of treatment response in patients with lung cancer. This expert group recommends multi-detector computed tomography as the technique of choice for investigating this disease. The radiology report should include a full assessment by the TNM staging system. Lastly, when the patient is on immunotherapy, response evaluation should employ not only response evaluation criteria in solid tumours, but also immune-related response criteria.
Collapse
|
61
|
Karachaliou N, Drozdowskyj A, Gimenez-Capitan A, Morales-Espinosa D, Moran T, Costa EC, Cobo M, Domine M, Bover I, Camps C, Pulla MP, Vergnenegre A, Lopez-Vivanco G, Tarruella MM, Viteri S, Sureda BM, Rosell R. Palb2 Mrna Expression As a Predictive and Prognostic Marker in Advanced Non-Small-Cell Lung Cancer (Nsclc) Patients (P) Treated with Cisplatin- Docetaxel Chemotherapy. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu326.20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
62
|
Goss G, Felip E, Cobo M, Lu S, Syrigos K, Lee K, Göker E, Georgoulias V, Li W, Isla D, Morabito A, Guclu S, Min Y, Ardizzoni A, Gadgeel S, Love J, Chand V, Soria JC. A Randomized, Open-Label, Phase III Trial of Afatinib (A) Vs Erlotinib (E) As Second-Line Treatment of Patients (Pts) with Advanced Squamous Cell Carcinoma (Scc) of the Lung Following First-Line Platinum-Based Chemotherapy: Lux-Lung 8 (Ll8). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
63
|
Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, Bover I, Wang L, Provencio M, Yu L, Chaib I, You C, Massuti B, Song Y, Vergnenegre A, Lu H, Lopez-Vivanco G, Hu W, Robinet G, Yan J, Insa A, Xu X, Majem M, Chen X, de Las Peñas R, Karachaliou N, Sala MA, Wu Q, Isla D, Zhou Y, Baize N, Zhang F, Garde J, Germonpre P, Rauh S, ALHusaini H, Sanchez-Ronco M, Drozdowskyj A, Sanchez JJ, Camps C, Liu B, Rosell R, Colinet B, De Grève J, Germonpré P, Chen H, Chen X, Du J, Gao Y, Hu J, Hu W, Kong W, Li L, Li R, Li X, Liu B, Liu J, Lu H, Qian X, Ren W, Song Y, Wang L, Wei J, Wen L, Wu Q, Xiao X, Xu X, Yan J, Yang J, Yang M, Yang Y, Yin J, You C, Yu L, Yue X, Zhang F, Zhang J, Zhou Y, Zhu L, Zou Z, Baize N, Bombaron P, Chouaid C, Dansin E, Fournel P, Fraboulet G, Gervais R, Hominal S, Kahlout S, Lecaer H, Lena H, LeTreut J, Locher C, Molinier O, Monnet I, Oliviero G, Robinet G, Schoot R, Thomas P, Vergnènegre A, Berchem G, Rauh S, Al Husaini H, Aparisi F, Arriola E, Ballesteros I, Barneto I, Bernabé R, Blasco A, Bosch-Barrera J, Bover I, Calvo de Juan V, Camps C, Carcereny E, Catot S, Cobo M, De Las Peñas R, Dómine M, Felip E, García-Campelo MR, García-Girón C, García-Gómez R, Garcia-Sevila R, Garde J, Gasco A, Gil J, González-Larriba JL, Hernando-Polo S, Jantus E, Insa A, Isla D, Jiménez B, Lianes P, López-López R, López-Martín A, López-Vivanco G, Macias JA, Majem M, Marti-Ciriquian JL, Massuti B, Montoyo R, Morales-Espinosa D, Morán T, Moreno MA, Pallares C, Parera M, Pérez-Carrión R, Porta R, Provencio M, Reguart N, Rosell R, Rosillo F, Sala MA, Sanchez JM, Sullivan I, Terrasa J, Trigo JM, Valdivia J, Viñolas N, Viteri S, Botia-Castillo M, Mate JL, Perez-Cano M, Ramirez JL, Sanchez-Rodriguez B, Taron M, Tierno-Garcia M, Mijangos E, Ocaña J, Pereira E, Shao J, Sun X, O'Brate R. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. Ann Oncol 2014; 25:2147-2155. [PMID: 25164908 DOI: 10.1093/annonc/mdu389] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND In a Spanish Lung Cancer Group (SLCG) phase II trial, the combination of BRCA1 and receptor-associated protein 80 (RAP80) expression was significantly associated with outcome in Caucasian patients with nonsmall-cell lung cancer (NSCLC). The SLCG therefore undertook an industry-independent collaborative randomized phase III trial comparing nonselected cisplatin-based chemotherapy with therapy customized according to BRCA1/RAP80 expression. An analogous randomized phase II trial was carried out in China under the auspices of the SLCG to evaluate the effect of BRCA1/RAP80 expression in Asian patients. PATIENTS AND METHODS Eligibility criteria included stage IIIB-IV NSCLC and sufficient tumor specimen for molecular analysis. Randomization to the control or experimental arm was 1 : 1 in the SLCG trial and 1 : 3 in the Chinese trial. In both trials, patients in the control arm received docetaxel/cisplatin; in the experimental arm, patients with low RAP80 expression received gemcitabine/cisplatin, those with intermediate/high RAP80 expression and low/intermediate BRCA1 expression received docetaxel/cisplatin, and those with intermediate/high RAP80 expression and high BRCA1 expression received docetaxel alone. The primary end point was progression-free survival (PFS). RESULTS Two hundred and seventy-nine patients in the SLCG trial and 124 in the Chinese trial were assessable for PFS. PFS in the control and experimental arms in the SLCG trial was 5.49 and 4.38 months, respectively [log rank P = 0.07; hazard ratio (HR) 1.28; P = 0.03]. In the Chinese trial, PFS was 4.74 and 3.78 months, respectively (log rank P = 0.82; HR 0.95; P = 0.82). CONCLUSION Accrual was prematurely closed on the SLCG trial due to the absence of clinical benefit in the experimental over the control arm. However, the BREC studies provide proof of concept that an international, nonindustry, biomarker-directed trial is feasible. Thanks to the groundwork laid by these studies, we expect that ongoing further research on alternative biomarkers to elucidate DNA repair mechanisms will help define novel therapeutic approaches. TRIAL REGISTRATION NCT00617656/GECP-BREC and ChiCTR-TRC-12001860/BREC-CHINA.
Collapse
|
64
|
Mongil R, Cobo M, Galvez MV, Bermejo EJ, Pages C, Arrabal R. P-203 * QUANTITATIVE DETERMINATION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE ABERRANT METHYLATION IN NON-SMALL-CELL LUNG CANCER: A COMPARATIVE ANALYSIS IN TUMOUR TISSUE, NORMAL LUNG TISSUE, PERIPHERAL BLOOD, SPUTUM AND BRONCHIAL ASPIRATE. Interact Cardiovasc Thorac Surg 2014. [DOI: 10.1093/icvts/ivu167.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
65
|
Caballero J, del Campo R, Cobo M, Chinchón G, López-Causapé C, Antonio O, Tato M, Cantón R. 59 Population structure and antimicrobial susceptibility of Pseudomonas aeruginosa from a national survey involving 24 cystic fibrosis units in Spain. J Cyst Fibros 2014. [DOI: 10.1016/s1569-1993(14)60196-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
66
|
Caballero J, Cobo M, Chinchón G, López-Causapé C, Oliver A, de la Pedrosa EG, del Campo R, Tato M, Cantón R. 83 Bronchopulmonary infection/colonization in cystic fibrosis: results from a Spanish multicenter study. J Cyst Fibros 2014. [DOI: 10.1016/s1569-1993(14)60219-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
67
|
Douillard JY, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A, Milenkova T. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 2013; 110:55-62. [PMID: 24263064 PMCID: PMC3887309 DOI: 10.1038/bjc.2013.721] [Citation(s) in RCA: 300] [Impact Index Per Article: 27.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2013] [Revised: 10/17/2013] [Accepted: 10/21/2013] [Indexed: 01/14/2023] Open
Abstract
Background: Phase-IV, open-label, single-arm study (NCT01203917) to assess efficacy and safety/tolerability of first-line gefitinib in Caucasian patients with stage IIIA/B/IV, epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Methods: Treatment: gefitinib 250 mg day−1 until progression. Primary endpoint: objective response rate (ORR). Secondary endpoints: disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety/tolerability. Pre-planned exploratory objective: EGFR mutation analysis in matched tumour and plasma samples. Results: Of 1060 screened patients with NSCLC (859 known mutation status; 118 positive, mutation frequency 14%), 106 with EGFR sensitising mutations were enrolled (female 70.8% adenocarcinoma 97.2% never-smoker 64.2%). At data cutoff: ORR 69.8% (95% confidence interval (CI) 60.5–77.7), DCR 90.6% (95% CI 83.5–94.8), median PFS 9.7 months (95% CI 8.5–11.0), median OS 19.2 months (95% CI 17.0–NC; 27% maturity). Most common adverse events (AEs; any grade): rash (44.9%), diarrhoea (30.8%); CTC (Common Toxicity Criteria) grade 3/4 AEs: 15% SAEs: 19%. Baseline plasma 1 samples were available in 803 patients (784 known mutation status; 82 positive; mutation frequency 10%). Plasma 1 EGFR mutation test sensitivity: 65.7% (95% CI 55.8–74.7). Conclusion: First-line gefitinib was effective and well tolerated in Caucasian patients with EGFR mutation-positive NSCLC. Plasma samples could be considered for mutation analysis if tumour tissue is unavailable.
Collapse
|
68
|
Garcia-Pavia P, Guzzo Merello G, Cobo M, Segovia J, Gomez-Bueno M, Bornstein B, Alonso-Pulpon L. Prevalence of Lamin A/C mutations and digenetic Lamin A/C and desmosomal genes mutations among idiopathic dilated cardiomyopathy heart transplant recipients. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht309.p4234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
69
|
Douillard J, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A, Milenkova T. 68O EFFICACY, SAFETY AND TOLERABILITY RESULTS FROM A PHASE IV, OPEN-LABEL, SINGLE ARM STUDY OF 1ST-LINE GEFITINIB IN CAUCASIAN PATIENTS (PTS) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC). Lung Cancer 2013. [DOI: 10.1016/s0169-5002(13)70288-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
70
|
Provencio M, Camps C, Cobo M, De las Peñas R, Massuti B, Blanco R, Alberola V, Jimenez U, Delgado JR, Cardenal F, Tarón M, Ramírez JL, Sanchez A, Rosell R. Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. Cancer Chemother Pharmacol 2012; 70:883-90. [PMID: 23053267 DOI: 10.1007/s00280-012-1985-9] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2012] [Accepted: 09/17/2012] [Indexed: 11/25/2022]
Abstract
PURPOSE New therapeutic approaches are being developed based on findings that several genetic abnormalities underlying non-small-cell lung cancer (NSCLC) can influence chemosensitivity. The identification of molecular markers, useful for therapeutic decisions in lung cancer, is thus crucial for disease management. The present study evaluated single-nucleotide polymorphisms (SNPs) in XRCC3, XPD and Aurora kinase A in NSCLC patients in order to assess whether these biomarkers were able to predict the outcomes of the patients. METHODS The Spanish Lung Cancer Group prospectively assessed this clinical study. Eligible patients had histologically confirmed stage IV or IIIB (with malignant pleural effusion) NSCLC, which had not previously been treated with chemotherapy, and a World Health Organization performance status (PS) of 0-1. Patients received intravenous doses of vinorelbine 25 mg/m(2) on days 1 and 8, and cisplatin 75 mg/m(2) on day 1, every 21 days for a maximum of 6 cycles. Venous blood was collected from each, and genomic DNA was isolated. SNPs in XRCC3 T241M, XPD K751Q, XPD D312N, AURORA 91, AURORA 169 were assessed. RESULTS The study included 180 patients. Median age was 62 years; 87 % were male; 34 % had PS 0; and 83 % had stage IV disease. The median number of cycles was 4. Time to progression was 5.1 months (95 % CI, 4.2-5.9). Overall median survival was 8.6 months (95 % CI, 7.1-10.1). There was no significant association between SNPs in XRCC3 T241M, XPD K751Q, XPD D312N, AURORA 91, AURORA 169 in outcome or toxicity. CONCLUSIONS Our findings indicate that SNPs in XRCC3, XPD or Aurora kinase A cannot predict outcomes in advanced NSCLC patients treated with platinum-based chemotherapy.
Collapse
|
71
|
Sarralde J, Fernández-Divar J, Cobo M, Burgos V, Gutiérrez J, Nistal J, Solórzano L, Tascón V. 140. Asistencia circulatoria mecánica como puente al trasplante cardíaco. herramienta fundamental en un programa trasplantador. CIRUGIA CARDIOVASCULAR 2012. [DOI: 10.1016/s1134-0096(12)70432-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
72
|
Viñolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sánchez-Torres JM, Barón FJ, Cobo M, Maestu I, Moreno I, Mesía C, Izquierdo A, Felip E, López-Brea M, Márquez A, Sánchez-Ronco M, Tarón M, Santarpia MC, Rosell R. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 2011; 71:191-8. [PMID: 20627363 DOI: 10.1016/j.lungcan.2010.05.005] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2010] [Revised: 03/30/2010] [Accepted: 05/02/2010] [Indexed: 10/19/2022]
Abstract
UNLABELLED New therapeutic approaches are being developed based on the findings that several genetic abnormalities underlying NSCLC could influence chemosensitivity. In this study, we assessed whether the presence of polymorphisms in ERCC1, XPD, RRM1 and MDR1 genes can affect the efficacy and the tolerability of cisplatin and vinorelbine in NSCLC patients. MATERIAL AND METHODS Eligible patients had histological confirmed stage IV or IIIB (with malignant pleural effusion) non-small-cell lung cancer (NSCLC) previously untreated with chemotherapy; World Health Organization performance status (PS) 0-1. Patients received intravenous doses of vinorelbine 25 mg/m² on day 1 and 8 and cisplatin 75 mg/m² on day 1, every 21 days, for a maximum of eight cycles. RESULTS 94 patients were included. Median age was 61 years; 84% were male; WHO performance status (PS) was 0 in 24%; and 88% of patients had stage IV disease. The median number of cycles was 6. Overall median survival was 10.92 months (95% CI 9.0-12.9). Overall median time to progression was 5.89 months (95% CI 5.2-6.6). Results of the multivariate analysis for time to progression showed that ECOG 0 (hazard ratio [HR] ECOG 1 vs. ECOG 0, 1.74; p=0.036), MDR13435CC (HR CT vs. CC, 2.01; p=0.017; HR TT vs. CC, 1.54; p=0.22), and decreasing age (HR of age, 0.97; p=0.016) were the most powerful prognostic factors significantly related to lower risk of progression. Whereas ECOG 0 was the only prognostic factor for survival (HR ECOG 1 vs. ECOG 0, 3.02; p=0.001). There was no significant association between any of the SNPs analysed and the occurrence of vinorelbine and cisplatin-related toxicity. CONCLUSION In our results, the most important prognostic factors associated with lower risk of progression were MDR1 3435 CC genotype, PS 0 and younger age.
Collapse
|
73
|
Oramas J, Cobo M, Paredes A, Arriola E, Sala M, Artal A, Girones R, Martinez M, Figueroa S, Domine M. 9075 POSTER ARIADNA Study – Evaluation of Symptoms on Daily Life and Health-related Quality of Life (HRQoL) of Patients With Advanced Non-small Cell Lung Cancer (NSCLC). Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72387-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
74
|
Massuti B, Jimenez U, Rodriguez Paniagua JM, Pun YW, Cobo M, Carcereny Costa E, Arrabal R, Astudillo J, Barneto IC, De Las Penas R, Baamonde C, Sales G, Gonzalez-Larriba J, Lopez-Vivanco G, Hernando-Trancho F, Pac J, Artal-Cortes A, Rivas J, Rosell R, Sanchez JM. SCAT trial: Phase III Spanish customized adjuvant treatment according BRCA1 mRNA levels in stage II-IIIA non-small cell lung cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
75
|
De Castro J, Domine M, Garcia-Bueno J, Saura S, García R, Sereno M, Juan Vidal O, Pujol E, Rubio-Viqueira B, Cobo M. Clinical outcomes for special populations of patients treated with first-line bevacizumab-based therapy in an observational study (AVVA). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e18033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|